AU2479695A - Prevention of tumor metastasis - Google Patents

Prevention of tumor metastasis

Info

Publication number
AU2479695A
AU2479695A AU24796/95A AU2479695A AU2479695A AU 2479695 A AU2479695 A AU 2479695A AU 24796/95 A AU24796/95 A AU 24796/95A AU 2479695 A AU2479695 A AU 2479695A AU 2479695 A AU2479695 A AU 2479695A
Authority
AU
Australia
Prior art keywords
prevention
tumor metastasis
metastasis
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24796/95A
Other languages
English (en)
Inventor
David Naor
Elimelech Okon
Muayad Zahalka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Hadasit Medical Research Services and Development Co
Publication of AU2479695A publication Critical patent/AU2479695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU24796/95A 1994-05-09 1995-05-09 Prevention of tumor metastasis Abandoned AU2479695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24006494A 1994-05-09 1994-05-09
PCT/US1995/005819 WO1995030439A2 (fr) 1994-05-09 1995-05-09 Prevention de la metastase des tumeurs
US240064 1999-01-29

Publications (1)

Publication Number Publication Date
AU2479695A true AU2479695A (en) 1995-11-29

Family

ID=22904974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24796/95A Abandoned AU2479695A (en) 1994-05-09 1995-05-09 Prevention of tumor metastasis

Country Status (2)

Country Link
AU (1) AU2479695A (fr)
WO (1) WO1995030439A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732323C2 (de) * 1996-08-06 1999-08-19 Dunzendorfer Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AU2004230482A1 (en) * 2003-04-15 2004-10-28 Biozyme Laboratories, Ltd Process for isolating and purifing ovine hyaluronidase
EP1912658B1 (fr) 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Protocoles thérapeutiques utilisant le hyaluronan
JP5627181B2 (ja) 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法
DE102007054877A1 (de) * 2007-11-15 2009-05-20 Dieter Dr. med. Wetzel Verwendung von Hyaluronidase als Arzneimittel zur Behandlung einer Lebererkrankung mit profibrogener Stoffwechsellage
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP2890383A2 (fr) * 2012-08-31 2015-07-08 Vib Vzw Modulation de la migration transendothéliale et du recrutement de granulocytes par la modulation de la voie c-met
EP4284947A1 (fr) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4

Also Published As

Publication number Publication date
WO1995030439A3 (fr) 1996-01-25
WO1995030439A2 (fr) 1995-11-16

Similar Documents

Publication Publication Date Title
AU2402395A (en) Cancer treatment and metastasis prevention
AU3299195A (en) Inhibition of helicobacter
EP0708445A3 (fr) Fabrication de disques
GB2330182B (en) Manufacture of gaskets
GB9512290D0 (en) Uses of polyhexanide
AU2479695A (en) Prevention of tumor metastasis
AU2217797A (en) Synthesis of indolylmaleimides
AU1210797A (en) Cancerous metastasis inhibitor
AU3402793A (en) Imidazolyl-substituted phenylacetamides
AU4157097A (en) Synthesis of bisindolylmalimides
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AUPM806694A0 (en) Rendering of overlapping objects
GB9311130D0 (en) Tumor metastasis gene
GB2301636B (en) Manufacture of gaskets
AU3948395A (en) Synthesis of 6-azaandrostenones
AU5126298A (en) Inhibition of crib-biting
GB9722451D0 (en) The manufacture of gaskets
AU1895295A (en) Gasket
AU3370095A (en) Methods of inhibiting endometrial cancer
AU3178095A (en) Rendering of overlapping objects
AU3221995A (en) Phenylacetamides having leukotriene-antagonistic action
AU1954895A (en) Pressure-retention gasket
GB2288807B (en) Production of delta-latroinsectotoxin
AU2077695A (en) Gaskets
AU3655697A (en) Synthesis of haloalkynol